Abiraterone Acetate 250mg Specific Drug

Name: Abiraterone Acetate 250mg
Availability: InStock

Price Trend: 259.59-273.26 USD / Bottle

Get Latest Price

Minimum Order Quantity :

3 Bottle

In Stock

Product Specifications

Drug Type	Specific Drug
Ingredients	ABIRATERONE 250
Physical Form	Tablets
Function	Cancer Treatment
Dosage	Prostate Cancer Metastatic castration-resistant prostate cancer Zytiga Indicated in combination with prednisone for patients with metastatic castration-resistant prostate cancer (CRPC) 1000 mg (two 500-mg tablets or four 250-mg tablets) PO qDay with prednisone 5 mg PO q12hr Yonsa Indicated in combination with methylprednisolone for the treatment of patients with metastatic CRPC 500 mg (four 125-mg tablets) PO qDay in combination with methylprednisolone 4 mg PO BID Metastatic high-risk castration-sensitive prostate cancer Zytiga Indicated in combination with prednisone for patients with metastatic high-risk castration-sensitive prostate cancer (CSPC) 1000 mg (two 500-mg tablets or four 250-mg tablets) PO qDay with prednisone 5 mg PO q12hr Dosage Modifications Strong CYP3A4 inducers Coadministration with strong CYP3A4 inducers (eg, phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital): Avoid if possible; if strong CYP3A4 inducer must be administered, increase abiraterone dosage frequency of abiraterone Reduce dose back to the previous dose and frequency, if the concomitant strong CYP3A4 inducer is discontinued Yonsa Increase from 500 mg qDay to 500 mg BID Zytiga Increase from 1000 mg qDay to 1000 mg BID Hepatic impairment (Zytiga) Baseline LFTs Mild (Child-Pugh A): No dosage adjustment necessary Moderate (Child-Pugh B): Reduce starting dose to 250 mg PO qDay; monitor ALT, AST, and bilirubin prior to start of treatment, qWeek for the first month, q2Weeks for the following 2 months of treatment and monthly thereafter If elevations in ALT and/or AST >5x ULN or total bilirubin >3x ULN occur in patients with baseline moderate hepatic impairment, discontinue abiraterone and do not retreat patients Severe (Child-Pugh C): Do not use Increased LFTs during treatment ALT and/or AST >5x ULN or total bilirubin >3x ULN: Interrupt treatment; reinitiate at reduced dose of 750 mg PO qDay following return of LFTs to baseline or to AST/ALT a%0$?2.5x ULN and total bilirubin a%0$?1.5x ULN For patients who resume treatment, monitor serum transaminases and bilirubin at least q2Weeks for 3 months, and then monthly thereafter If hepatotoxicity recurs at 750 mg/day, may restart at 500 mg/day (after LFTs decrease as above) If hepatoxicity recurs at reduced dose of 500 mg/day, discontinue treatment Permanently discontinue treatment for patients who develop a concurrent elevation of ALT >3x ULN and total bilirubin >2x ULN in the absence of biliary obstruction or other causes responsible for the concurrent elevation Hepatic impairment (Yonsa) Baseline Moderate (Child-Pugh Class B): Reduce 125 mg PO qDay; monitor ALT, AST, and bilirubin prior to the start of treatment, every week for the first month, q2Weeks for the following 2 months of treatment and monthly thereafter If elevations in ALT and/or AST >5x ULN or total bilirubin >3x ULN occur in patients with baseline moderate hepatic impairment: Discontinue treatment and do not retreat patients with abiraterone Severe (Child-Pugh Class C): Do not use Increased LFTs during treatment ALT and/or AST >5x ULN or total bilirubin >3x ULN): Interrupt treatment; restart at a reduced dose of 375 mg qDay following return of liver function tests to the patientaEURtms baseline or to AST and ALT a%0$?2.5x ULN and total bilirubin a%0$?1.5x ULN For patients who resume treatment, monitor serum transaminases and bilirubin at least q2Weeks for 3 months, and then monthly thereafter If hepatotoxicity recurs on 375 mg/day, may be restart aeduced dose of 250 mg/day (after LFTs decrease as above) I
Suitable For	Adults, Aged Person
Quantity	5 Boxes
Storage Instructions	ROOM TEMP. 10 -30 C
Payment Terms	Cash in Advance (CID)
Supply Ability	50 Per Day
Delivery Time	2 Week
Packaging Details	1*120 TAB/BOTT
Main Export Market(s)	Australia, Central America, North America, South America, Eastern Europe, Western Europe, Middle East, Africa, Asia
Main Domestic Market	All India

Product Overview

Key Features

Company Details

Business Type

Exporter, Supplier, Trading Company

Employee Count

Establishment

2003

Working Days

Monday To Sunday

GST NO

27ADJPR6506L1Z1

Payment Mode

Cash in Advance (CID)

Explore Related Categories

Abiraterone Acetate Tablets

Glatiramer Acetate

More Products From This Seller

Azacitidine Injection - Powder Form, 100 mg per Unit | Treatment for Blood Cancer, Myelodysplastic Syndrome, Dosage Adjustments per Doctor's Guidance

Altretamine Tab Generic Drugs

Pregabalin 75 Capsules Generic Drugs

Melithion Injection Ingredients: Flupenthixol 20

Supatret 0.1 Aqueous Gel - 100 Units | Anti-Bacterial, Reduces Oil Production, Suitable for All Skin Types, Treats Acne and Prevents Scarring

AZITHROMYCIN - 500 mg Film Coated Tablets | Broad-Spectrum Antibiotic for Various Bacterial Infections, Suitable for All

Supatret C Gel External Use Drugs

Retin-A Gel

Kojic Cream - 50 Units of Hyperpigmentation Treatment | External Use Drug, Contains Kojic Acid, Suitable for All Skin Types, Store at Room Temperature 10-30°C

Retino Ac Gel External Use Drugs

Seller Details

Shrestha Global Pharma

GST - 27ADJPR6506L1Z1

Rating

Nagpur, Maharashtra

Accepts only Foreign inquiries

Proprietor

Mr Saroj Roy

Address

B No. 95, Aradhana Colony, Nara Road, Jaripatka, Nagpur, Maharashtra, 440014, India

abiraterone acetate in Nagpur

Report incorrect details

Recommended Products

Abiraterone Acetate

Wecare Pharma

Abirapro Abiraterone Acetate Tablets

Drug Mart

Abiraterone Acetate Tablet - 250mg | Premium Quality Anti-Androgen, Efficacious Treatment for Prostate Cancer, Minimal Side Effects

Spark Lifesciences

Bdron 500Mg Tablets Specific Drug

Shrestha Global Pharma

Xbira 250 Specific Drug

Shrestha Global Pharma

250 mg Abiraterone Acetate Tablets - 250 mg Dosage, Used in Prostate Cancer Treatment, 120 Tablets Per Box, Store in Cool, Dry Place

Saismita Healthcare

Abiraterone Acetate Tablets - 250mg, Anti-Testosterone Formula for Prostate Cancer Treatment, Moisture-Proof Packaging of 120 Tablets, Balanced Composition with Reduced Side Effects

Poss Multitrade Pvt. Ltd.

Abiraterone Acetate Tablets - Prescription Medicine for Advanced Prostate Cancer Treatment | Dosage as Directed by Physician, Store in Cool and Dry Place

Spark Lifesciences

Compare With Similar Products

Product Name

Abiraterone Acetate 250mg

Bdron 500 Mg Tab

Abiraterone Acetate Tablets

Buyer Feedback

Response Rate

100

Price Or Price Range

259.59-273.26 USD ($) (Approx.)

21600 INR (Approx.)

1 USD ($) (Approx.)

Minimum Order Quantity

3 Bottle/Bottles

100 Tablet

1 Unit/Units

Drug Type

Specific Drug

General Medicines

Ingredients

ABIRATERONE 250

Abiraterone Acetate

Physical Form

Tablets

Function

Cancer Treatment

Anti-Cancer

Dosage

Prostate Cancer Metastatic castration-resistant prostate cancer Zytiga Indicated in combination with prednisone for patients with metastatic castration-resistant prostate cancer (CRPC) 1000 mg (two 500-mg tablets or four 250-mg tablets) PO qDay with prednisone 5 mg PO q12hr Yonsa Indicated in combination with methylprednisolone for the treatment of patients with metastatic CRPC 500 mg (four 125-mg tablets) PO qDay in combination with methylprednisolone 4 mg PO BID Metastatic high-risk castration-sensitive prostate cancer Zytiga Indicated in combination with prednisone for patients with metastatic high-risk castration-sensitive prostate cancer (CSPC) 1000 mg (two 500-mg tablets or four 250-mg tablets) PO qDay with prednisone 5 mg PO q12hr Dosage Modifications Strong CYP3A4 inducers Coadministration with strong CYP3A4 inducers (eg, phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital): Avoid if possible; if strong CYP3A4 inducer must be administered, increase abiraterone dosage frequency of abiraterone Reduce dose back to the previous dose and frequency, if the concomitant strong CYP3A4 inducer is discontinued Yonsa Increase from 500 mg qDay to 500 mg BID Zytiga Increase from 1000 mg qDay to 1000 mg BID Hepatic impairment (Zytiga) Baseline LFTs Mild (Child-Pugh A): No dosage adjustment necessary Moderate (Child-Pugh B): Reduce starting dose to 250 mg PO qDay; monitor ALT, AST, and bilirubin prior to start of treatment, qWeek for the first month, q2Weeks for the following 2 months of treatment and monthly thereafter If elevations in ALT and/or AST >5x ULN or total bilirubin >3x ULN occur in patients with baseline moderate hepatic impairment, discontinue abiraterone and do not retreat patients Severe (Child-Pugh C): Do not use Increased LFTs during treatment ALT and/or AST >5x ULN or total bilirubin >3x ULN: Interrupt treatment; reinitiate at reduced dose of 750 mg PO qDay following return of LFTs to baseline or to AST/ALT a%0$?2.5x ULN and total bilirubin a%0$?1.5x ULN For patients who resume treatment, monitor serum transaminases and bilirubin at least q2Weeks for 3 months, and then monthly thereafter If hepatotoxicity recurs at 750 mg/day, may restart at 500 mg/day (after LFTs decrease as above) If hepatoxicity recurs at reduced dose of 500 mg/day, discontinue treatment Permanently discontinue treatment for patients who develop a concurrent elevation of ALT >3x ULN and total bilirubin >2x ULN in the absence of biliary obstruction or other causes responsible for the concurrent elevation Hepatic impairment (Yonsa) Baseline Moderate (Child-Pugh Class B): Reduce 125 mg PO qDay; monitor ALT, AST, and bilirubin prior to the start of treatment, every week for the first month, q2Weeks for the following 2 months of treatment and monthly thereafter If elevations in ALT and/or AST >5x ULN or total bilirubin >3x ULN occur in patients with baseline moderate hepatic impairment: Discontinue treatment and do not retreat patients with abiraterone Severe (Child-Pugh Class C): Do not use Increased LFTs during treatment ALT and/or AST >5x ULN or total bilirubin >3x ULN): Interrupt treatment; restart at a reduced dose of 375 mg qDay following return of liver function tests to the patientaEURtms baseline or to AST and ALT a%0$?2.5x ULN and total bilirubin a%0$?1.5x ULN For patients who resume treatment, monitor serum transaminases and bilirubin at least q2Weeks for 3 months, and then monthly thereafter If hepatotoxicity recurs on 375 mg/day, may be restart aeduced dose of 250 mg/day (after LFTs decrease as above) I

As suggested

Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Xbira 250mg Tablet is to be taken empty stomach.

Suitable For

Adults, Aged Person

Adults

Suitable For All, Adults, Women, Children, Aged Person, Teenagers

Storage Instructions

ROOM TEMP. 10 -30 C

cold & dry place

Store below 30AdegC

Payment Terms

Cash in Advance (CID)

Paypal, Letter of Credit (L/C), Letter of Credit at Sight (Sight L/C), Telegraphic Transfer (T/T), Others, Cash in Advance (CID), Cash Advance (CA)

Supply Ability

50 Per Day

1000 Per Day

Delivery Time

2 Week

7 Days

Packaging Details

1*120 TAB/BOTT

120 tablets in 1 bottle

Main Export Market(s)

Australia, Central America, North America, South America, Eastern Europe, Western Europe, Middle East, Africa, Asia

Australia, North America, South America, Eastern Europe, Western Europe, Middle East, Central America, Asia, Africa

Australia, North America, South America, Eastern Europe, Western Europe, Middle East, Africa, Central America, Asia

Main Domestic Market

All India

Dosage Guidelines

As Suggested

Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Xbira 250mg Tablet is to be taken empty stomach.

Sold By

Shrestha Global Pharma
Nagpur, Maharashtra